16. Ibrance

Ibrance flopped a major breast cancer trial back in May. (Pfizer)

Company: Pfizer
2019 sales: $4.96 billion
Projected 2026 sales: $11.04 billion
Projected CAGR: +12%
Used for: HR-postiive, HER2-negative breast cancer

Pfizer's oncology med Ibrance has been a sales superstar since its launch in 2015, and for years execs forecast even brighter days ahead with a move earlier into therapy. A continued sales climb would be great for Pfizer, which is looking for for growth drivers after its planned generics unit spinoff—but they may not come in that arena.

Ibrance hit $4.96 billion in sales in 2019 on the strength of its market share in HR-positive, HER2-negative breast cancer. And there's even more room for growth: Evaluate Pharma predicts the drug could climb all the way to $11.04 billion in sales by 2026, putting it among pharma's sales elites. 

But Ibrance missed a huge opportunity at a multibillion-dollar market when it flopped a major early breast cancer trial in May.

RELATED: Pfizer's Ibrance misses shot at big new market with early breast cancer failure

16. Ibrance

Suggested Articles

The next wave of immuno-oncology R&D includes drugs that interact with a wide range of emerging immune targets, including TIGIT and CD47.

Emerging targets like KRAS, MET and RET are inspiring novel kinase inhibitor development and fueling billions in pharma deals.

Despite the rise of cell therapies to treat cancer, R&D centered on novel tyrosine kinase inhibitors and immuno-oncology targets is booming.